Skip to content

Breast Cancer Health Center

Font Size

Genetics of Breast and Ovarian Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Psychosocial Issues in Inherited Breast and Ovarian Cancer Syndromes

Table 15. Uptake of Risk-reducing Salpingo-oophorectomy (RRSO) and/or Gynecologic Screening AmongBRCA1andBRCA2Mutation Carriers

Study CitationStudy PopulationUptake of RRSOUptake of Gynecologic ScreeningLength of Follow-upComments
CA-125 = cancer antigen 125; RRM = risk-reducing mastectomy; TVUS = transvaginal ultrasound.
a Self-report as data source.
b Medical records as data source.
c Data source not specified.
United States
Scheuer et al. (2002)[225]Carriers (n = 179)aCarriers 50.3%CA-125Mean, 24.8 mo; range, 1.6–66.0 moWomen undergoing RRSO were older and more likely to have a personal history of breast cancer.
– Carriers 67.6%
– Carriers 72.9%
Beattie et al. (2009)[217]Carriers (n = 240)bCarriers 51%Not applicableMean, 3.7 yWomen opting for RRSO <60 y had a prior diagnosis of breast cancer and also underwent RRM.
Median time to RRSO: 123 days from receiving results.
O'Neill et al. (2010)[218]Carriers (n = 146)aCarriers 32%Not applicable12 mo 
Schwartz et al. (2012)[219]Carriers (n = 100)aCarriers 65%CA-125Mean, 5.3 yPredictors of RRSO were being ≥40 y and having received a diagnosis of breast cancer more than 10 y ago.
Noncarriers (n = 52)aNoncarriers 1.9%– Carriers 56%
– Noncarriers 12%
– Uninformative 33%
Uninformative (n = 203)aUninformative 13.3%TVUS
– Carriers 42%
– Noncarriers 20%
– Uninformative 26%
Garcia et al. (2013)[220]Carriers (n = 305)bCarriers 74%Excluding women post-RRSO:41 mo; range, 26–66 moOvarian surveillance decreased significantly from years 1–5 of follow-up; CA-125: 47% to 2%; TVUS: 45% to 2.3%
– Carriers 47%
– Carriers 45%
Mannis et al. (2013)[226]Carriers (n = 201)aCarriers 69.6%CA-125Median, 3.7 yPredictors of RRSO and screening included being aBRCAmutation carrier, age 40–49 y, having a higher income, ≥2 children, a personal history of breast cancer, and a first-degree relative with ovarian cancer.
– 26.3%
– 26.3%
Noncarriers (n = 103)aNoncarriers 2.0%Not reported
Uninformative (n = 773)a; 59/773 with a variant of uncertain significanceUninformative 12.3%CA-125
– 10.4%
– 6.5%
Singh et al. (2013)[221]Carriers (n = 136)bCarriers 52%Not applicableRange, 1–11 yPredictors of RRSO were first- or second-degree relative with breast cancer, a mother lost to pelvic cancer, having had ≥1 childbirths, age ≥50 y, and having undergone testing after 2005.
Phillips et al. (2006)[222]Carriers (n = 70)aCarriers 29%CA-1253 y 
– Carriers 0%
– Carriers 67%
Friebel et al. (2007)[227]Carriers (N = 537)cCarriers 55%Not applicableMinimum 6 mo; median 36 moRRSO greatest in parous women >40 y.
Madalinska et al. (2007)[228]Carriers (n = 160)a, bCarriers 74%Carriers 26%12 moWomen who underwent RRSO had lower education levels, viewed ovarian cancer as incurable, and believed strongly in the benefits of RRSO.
Specific method(s) of gynecological screening not reported.
Metcalfe et al. (2008)[223]Carriers (N = 2,677)aCarriers 57%Not applicable3.9 y; range, 1.5–10.3 yLarge differences in uptake of risk management options by country.
Julian-Reynier et al. (2011)[224]Carriers (n = 101)aCarriers 42.6%TVUS5 yRRSO uptake increased with age. Having undergone RRSO did not alter breast cancer risk perception. Noncarriers often continued screening.
Noncarriers (n = 145)aNoncarriers 2%– Noncarriers 43.2%
Rhiem et al. (2011)[229]Carriers (N = 306)bCarriers 57%Not evaluatedMean, 47.8 mo post-oophorectomyMedian age at time of RRSO = 47 y. One occult fallopian tube cancer was detected at the time of RRSO. One peritoneal carcinoma was diagnosed 26 mo post-RRSO.
Sidon et al. (2012)[230]Carriers (N = 700)a; 386/700 with personal history of breast cancerBRCA1carriers:Not evaluatedAffected with breast cancerUptake of RRSO was lower in women >60 y (22% uptake at 5 y). None of the women >70 y had a RRSO performed.
– 54.5%
BRCA2 carriers:–BRCA1: Mean, 2.29; range, 0.1–11.45 y
– 45.5%
All carriers with no personal history of breast cancer–BRCA2: Mean, 1.77; range, 0.1–11.1 y
Not affected with breast cancer
– 54.2%
All carriers with personal history of breast cancer–BRCA1: Mean, 1.63; range, 0.1–11.28 y
– 43.2%–BRCA2:Mean, 1.75; range, 0.1–8.98 y
Next Article:

Today on WebMD

Breast Cancer Overview
From self-exams and biopsies to reconstruction, we’ve got you covered.
Dealing with breast cancer
Get answers to your questions.
woman having mammogram
Experts don’t agree on all fronts, but you can be your own advocate.
woman undergoing breast cancer test
Many women worry. But the truth? Most abnormalities aren’t breast cancer.
Breast Cancer Treatments Improving
Resolved To Quit Smoking
Woman getting mammogram
Screening Tests for Women
ovarian cancer overview slideshow
serious woman
what is your cancer risk
10 Ways to Revitalize Slideshow